OPTIMIZING NON-ADDICTIVE DRUG DELIVERY
IN THE MANAGEMENT OF PAIN AND CNS DISORDERS
Virpax Pharmaceuticals specializes in developing novel and proprietary drug delivery systems across various pain indications in order to enhance compliance and optimize the ability of each product candidate in our pipeline.
Our improved drug-delivery systems, and targeted drug-releasing technologies are focused on advancing non-opioid and non-addictive pain management treatments and treatments for CNS disorders.
Virpax has global rights to a proprietary patented Molecular Envelope Technology (MET) that uses an intranasal device to deliver enkephalin via nanoparticles for the management of acute and chronic pain, including pain associated with cancer.
Virpax also has global rights to the proprietary MET enkephalin formulation to manage Post Traumatic Stress Disorder (PTSD).
Virpax has global rights to use a patented MET formulation to deliver pharmaceutical-grade cannabinol for the management of Epilepsy, a Rare Pediatric Disease.
Virpax has global rights to a patented topical spray film delivery technology for osteoarthritis of the knee.
Virpax has worldwide rights to a patented injectable “local anesthetic” liposomal hydrogel technology for postoperative pain management.
Virpax® Pharmaceuticals is a publicly held company (Nasdaq: VRPX) located in Berwyn, PA and is focused on the development and worldwide commercialization of its non-addictive pain and neurological pipeline.
Prescribers, regulators, and patients all seek non-addictive treatment options to combat the opioid epidemic. Virpax will utilize our drug delivery technologies to develop a pipeline of proprietary non-addictive pain product candidates for commercialization.
OUR MISSION
Our mission is to improve widely used and newly developed non-addictive pain medicines, as well as neurological product candidates, by optimizing our proprietary delivery systems.
We want to provide healthcare professionals and patients with effective solutions to manage pain and neurological issues worldwide.
EXPERIENCED
EXECUTIVE LEADERSHIP
ROBUST
PIPELINE
Epoladerm™
Diclofenac topical spray film
Epoladerm nonclinical studies have demonstrated improved drying times and less messy handling compared to topical gels/ointments. It’s an invisible application, therefore, more aesthetically appealing. Its pliable application allows for optimized use on contours of the knees.
Probudur™
Injectable long-acting bupivacaine hydrogel
Virpax will introduce its proprietary Probudur, a single injectable liposomal gel local anesthetic for postoperative pain management. Probudur will be the only liposomal gel bupivacaine with 96 hours of postoperative pain control; 24 hours longer than any other liposomal bupivacaine.
